Heparin to be less potent, FDA says

Share this article:
Manufacturers are expected to begin shipping a new kind of heparin product on Thursday.

Pharmacopeia has adopted new manufacturing controls for the anti-clotting drug. These include a revised reference standard for the drug's dose unit to guard against potential contamination. The revised standard is about 10% less potent than the former USP unit. The Food and Drug Administration last week notified healthcare providers of the change.

“Although the FDA-approved labeling for heparin has not changed, including the recommended doses, it is essential that health care professionals be aware of the potential difference in potency between the old and new vials of heparin when administering the drug,” said John Jenkins, director of the FDA's Office of New Drugs.

Share this article:

More in News

Rape investigation blocked by nursing home's HIPAA concerns, authorities say ...

Florida authorities say a nursing home is citing privacy laws to impede the investigation of a possible resident rape, according to local news reports.

Jury hands down $14 million negligent care verdict to 'send message' to nursing homes

Jury hands down $14 million negligent care verdict ...

A Massachusetts jury has awarded $14 million to the family of a nursing home resident who died due to a pressure ulcer, dehydration and other conditions linked to negligent care, ...

CCRC executive director salaries hold steady, therapy directors get boost

Continuing care retirement community executive director salaries have barely increased in the past year, while therapy and rehabilitation directors received a boost, a new report shows. The average salary for a therapy and rehab director is currently $95,905.